AFL
42
5
MAT
64
-4
NVDA
51
-3
OI
64
2
PNC
61
2
SE
55
-5
DVN
47
4
MO
65
6
URBN
51
-5
SYY
61
3
GE
70
-4
RHI
44
2
BDX
64
5
ABBV
50
4
BRK.B
33
-3
DE
56
3
MCHP
73
2
COST
56
2
DTE
52
5
AMT
39
2
AFL
42
5
MAT
64
-4
NVDA
51
-3
OI
64
2
PNC
61
2
SE
55
-5
DVN
47
4
MO
65
6
URBN
51
-5
SYY
61
3
GE
70
-4
RHI
44
2
BDX
64
5
ABBV
50
4
BRK.B
33
-3
DE
56
3
MCHP
73
2
COST
56
2
DTE
52
5
AMT
39
2
Financhill
Back

Viking Therapeutics, Inc. Stock Predictions

The Next Gold Rush

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Sell
43

VKTX
Viking Therapeutics, Inc.

Last Price:
$33.24
Seasonality Move:
23.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Exxon and Chevron Have an Unlikely New Competitor

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Viking Therapeutics, Inc. Stock Forecast

  • Over the next 52 weeks, Viking Therapeutics, Inc. has on average historically risen by 57.2% based on the past 10 years of stock performance.
  • Viking Therapeutics, Inc. has risen higher in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is Viking Therapeutics, Inc. Stock Undervalued?
    The current Viking Therapeutics, Inc. [VKTX] share price is $34.34. The Score for VKTX is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.
  • VKTX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Viking Therapeutics, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Viking Therapeutics, Inc. has on average historically risen by 57.2% based on the past 10 years of stock performance.

Viking Therapeutics, Inc. Stock Rating

Sell
43
Viking Therapeutics, Inc. (VKTX) is a Sell

Is Viking Therapeutics, Inc. overpriced?

  • Viking Therapeutics, Inc. has risen higher in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

Viking Therapeutics, Inc. Stock Price History

Is VKTX stock going to rise?

  • The current trend is relatively stagnant and VKTX is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
vikingtherapeutics.com

52-Week Data

52-Week High:
43.15
52-Week Low:
18.92

Prediction Charts

Market Cap:
3.9B
Price in USD:
34.34
Volume:
6.9M
Beta:
1.33

Technical Analysis

SMA50:
35.83
SMA100:
32.57
SMA200:
30.63
52-Wk Change:
1.21%

Stock Predictions

  • Is Viking Therapeutics, Inc. stock public?
    Yes, Viking Therapeutics, Inc. is a publicly traded company.
  • What is the Viking Therapeutics, Inc. stock quote today?
    The Viking Therapeutics, Inc. stock price is 34.34 USD today.
  • How to buy Viking Therapeutics, Inc. stock online?
    You can buy Viking Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-24 36.68 37.35 37.83 36.22
Dec-26 37.25 37.18 37.44 36.00
Dec-29 36.74 36.46 37.09 36.13
Dec-30 36.46 35.32 36.66 35.21
Dec-31 35.14 35.18 35.50 34.67
Jan-2 35.54 35.42 36.17 34.88
Jan-5 35.20 32.14 35.21 31.85
Jan-6 31.88 32.30 33.28 31.56
Jan-7 32.50 32.38 33.35 31.73
Jan-8 32.30 31.65 32.30 31.59
Jan-9 32.35 31.99 32.94 31.79
Jan-12 32.33 31.76 32.33 31.04
Jan-13 31.69 30.69 31.82 29.54
Jan-14 30.69 34.34 36.00 30.56

Viking Therapeutics, Inc. Earnings

Viking Therapeutics, Inc. Earnings Report: Per Share Viking Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Viking Therapeutics, Inc. Forecast Revenue Growth

Viking Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Viking Therapeutics, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.34 per share, a decrease next quarter of $0.00 per share, a decrease this year of $1.11 per share, and a decrease next year of $0.28 per share.

* Viking Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.